Carmot Therapeutics

收并购

Carmot Therapeutics is a pharmaceutical company pioneering a transformative drug discovery approach, Chemotype Evolution, to identify superior therapeutics for human diseases.By January 2018, the company had relocated its headquarters to a new facility in Berkeley, CA, and maintained a research site in Mission Bay, San Francisco.In February 2010, Carmot Therapeutics signed an exclusive license agreement to apply Sunesis Pharmaceuticals' Fragment-Based Lead Discovery (FBLD) technology (Chemotype Evolution) for identifying drug candidates in therapy areas that include inflammatory, metabolic and neurodegenerative diseases. Sunesis would retain rights to the technology for use in its future internal discoveries. Financial terms were undisclosed.In July 2011, Carmot Therapeutics was awarded a grant from The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for the discovery of FABP type 4 and 5 small molecule inhibitors. The studies could lead to therapeutics for obe

http://carmot-therapeutics.us/

470305

基本信息

公司全称

Carmot Therapeutics Inc
类型

代谢性疾病和癌症新药开发商
产业领域

医药研发/制造、化学&生物药
公司人数

15人以下
地址

740 Heinz Avenue BERKELEY CALIFORNIA 94710; US; Telephone: +18884024674;
联系电话

5105279251
邮箱

info@carmot.us
成立时间

2008-01-01

投融资

2024-01-29

收并购

Roche
2023-05-25

E~PreIPO

Deep Track Capital

Franklin Templeton Investments

Willett Advisors LLC

RA Capital

Millennium

5AM Ventures

The Column Group

Frazier Lifesciences Acquisition Corp

Janus Henderson Investors

Venrock Capital
2022-07-26

D轮

Deep Track Capital

Willett Advisors LLC

Horizons Ventures

RA Capital

The Column Group
2020-10-02

C轮

Amgen

Horizons Ventures

The Column Group
2018-01-17

B轮

Horizons Ventures

The Column Group
2010-04-12

A轮

The Column Group
加载更多

Carmot Therapeutics

基本信息

投融资

相关投融资企业